Back

Notification report


Full notification file


General information

Notification Number
B/NL/20/006

Member State to which the notification was sent
Netherlands

Date of acknowledgement from the Member State Competent Authority
08/05/2020

Title of the Project
A phase II safety, dose finding and feasibility trial of MB-CART2019.1in patients with relapsed or resistant B-NHL

Proposed period of release:
01/07/2020 to 31/12/2025

Name of the Institute(s) or Company(ies)
Erasmus MC, Erasmus MC
s-Gravendijkwal 230
Afdeling Urologie
Rotterdam 3015 CE
The Netherlands;


3. Is the same GMO release planned elsewhere in the Community?
No

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
Other: mammals

Identity of the GMO:
T cells transduced with a replication-deficient lentiviral vector harbouring the chimericantigen receptor for targeting CD20 and CD19.

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
HumanHomoSapiens---

European Commission administrative information

Consent given by the Member State Competent Authority:
Yes
21/07/2020 00:00:00
Remarks: